PolyPeptide Group Ltd header image

PolyPeptide Group Ltd

PPGN

Equity

ISIN CH1110760852 / Valor 111076085

SIX Swiss Exchange (2026-11-11)
CHF 40.40%

PolyPeptide Group Ltd
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

PolyPeptide Group Ltd is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of active pharmaceutical ingredients (APIs) for both proprietary and generic drugs. The company collaborates with pharmaceutical and biotechnology firms to support the creation and manufacturing processes of these essential components, which are critical in the formulation of various medications. With a focus on delivering high-quality APIs, PolyPeptide plays a significant role in the pharmaceutical supply chain, providing expertise and resources that enable its clients to bring their products to market efficiently and effectively.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (09.11.2026):

PolyPeptide Group Ltd — Q4 2025 / FY 2025: PolyPeptide reported full-year 2025 results showing strong top-line growth and a material improvement in operating profitability while remaining loss-making at the net income level; revenue was EUR 389.3m (+15.6% vs 2024) and EBITDA rose to EUR 46.8m (12.0% margin), with management issuing 2026 guidance of 20–25% revenue growth (constant currency) and an EBITDA margin in the mid‑to‑high teens.

Financial snapshot

Revenue EUR 389.3m (+15.6%); EBITDA EUR 46.8m (+84.4%) with margin 12.0% (2024: 7.5%); EBIT EUR 8.7m (2.2%); result for the year EUR -21.2m; basic EPS EUR -0.64. Cash and cash equivalents at year-end EUR 74.6m.

Revenue mix & pipeline

Commercial revenue represented 61% of total; metabolics increased to 57% of revenue (2024: 40%). Development revenue grew 29.9% while commercial revenue rose 7.9%. Active custom projects totaled 196; 30 new projects acquired in 2025.

Profitability drivers

EBITDA improvement attributed to higher production volumes, better utilization and operational efficiencies, and the ramp-up of the large-scale SPPS site in Braine‑l’Alleud. EBITDA uplift partly offset by ERP-related exceptional costs (~EUR 4.1m). Personnel costs rose 13.4% as the organization scaled.

Cash flow, capex and financing

Net cash from operating activities EUR 77.5m. Capex EUR 110.0m (28.2% of revenue) as major capacity projects progressed; free cash flow was EUR -31.4m. Customer prepayments contributed net inflows of EUR 27.4m in 2025 and cumulative net inflows of ~EUR 156m (2023–2025). Revolving credit facility availability remained (EUR 51m available) and short‑term shareholder facility drawn EUR 20m.

Capacity expansion & operations

Large-scale SPPS in Braine‑l’Alleud reached target utilization and potential revenue from the asset was upgraded (~EUR 100m → ~EUR 125m). Strasbourg SPPS capacity became operational; pre-built modules delivered to Malmö (mechanical completion underway); investments planned in Ambernath (India) and downstream expansion in Torrance.

Non-operating items and net loss

Financial result was EUR -28.7m (vs -10.8m prior year), driven mainly by unfavorable FX revaluation of intercompany loans and non‑cash financing components related to contract liabilities, which contributed to the reported net loss despite positive operating performance.

Guidance & medium‑term targets

2026 guidance: revenue +20–25% (constant currency) and EBITDA margin in the mid‑to‑high teens. Mid‑term targets reaffirmed: double 2023 revenue by 2028 and an EBITDA margin approaching 25% by 2028, with average capex of 15–20% of revenue. No dividend will be proposed for AGM 2026 as investments continue.

Summarized from source with an LLMView Source

Key figures

68.0%1Y
96.3%3Y
-63.1%5Y

Performance

44.6%1Y
47.9%3Y
59.3%5Y

Volatility

Market cap

1603 M

Market cap (USD)

Daily traded volume (Shares)

7,433

Daily traded volume (Shares)

1 day high/low

29.45 / 28.75

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Illumina Inc
Illumina Inc Illumina Inc Valor: 1111080
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.92%USD 212.93
GE Healthcare Technologies Inc
GE Healthcare Technologies Inc GE Healthcare Technologies Inc Valor: 123735674
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.26%USD 82.60
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.41%USD 159.85
BeiGene Ltd
BeiGene Ltd BeiGene Ltd Valor: 30165310
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.95%USD 419.98
STERIS PLC
STERIS PLC STERIS PLC Valor: 47027903
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.33%USD 256.27
Sanofi SA
Sanofi SA Sanofi SA Valor: 699381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.86%EUR 88.22
Xvivo Perfusion AB
Xvivo Perfusion AB Xvivo Perfusion AB Valor: 19661174
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.98%SEK 206.00
Cardinal Health Inc
Cardinal Health Inc Cardinal Health Inc Valor: 196652
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.24%USD 277.45
Royalty Pharma PLC
Royalty Pharma PLC Royalty Pharma PLC Valor: 55041695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.81%USD 70.01
Sienna Senior Living Inc
Sienna Senior Living Inc Sienna Senior Living Inc Valor: 28093100
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.49%CAD 20.50